Can-Fite BioPharma Overview
Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary drug candidates in phase II and phase III clinical development that address inflammatory, liver, and metabolic diseases. Can-Fite's platform technology utilizes the Gi protein-associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory, cancer, and other pathological body cells, whereas low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company's compounds bind with nM affinity to the A3AR and initiate deregulation of the NF-kB and Wnt signal transduction pathways, resulting in anti-inflammatory and anticancer effects.
Cumulative Funding Raised Over Time ($)
$3.2MApr 2019
$4.2MApr 2019
$7.2MApr 2025
$17.2MAug 2021
$22.2MAug 2024
$30.2MDec 2014
$37.4MFeb 2013
$42.4MFeb 2020
$47.4MJan 2017
$49.8MJan 2019
$57.3MJan 2023
$60.6MJul 2020
$68.7MJun 2020
$73.7MMar 2014
$78.7MMar 2018
$84.7MMay 2019
$89.5MOct 2015
$98.5MSep 2015
Latest News
growth-positive
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
Can-Fite BioPharma Ltd., a biotechnology company, announced a significant clinical finding under its compassionate use program for Namodenoson, a drug targeting oncological and inflammatory diseases. A patient with decompensated liver cirrhosis showed complete resolution of esophageal varices, a severe complication of advanced liver disease, after treatment with Namodenoson. This outcome suggests a potential disease-modifying effect of the drug. Namodenoson is currently in a Phase III clinical trial for hepatocellular carcinoma and other trials for different conditions. The findings may provide valuable insights for its ongoing development. The U.S. market for liver cirrhosis treatment is expected to grow significantly by 2030.
Product Stage
growth-positive
Can-Fite Reports H1 2025 Financial Results and Clinical Update
Can-Fite BioPharma Ltd., a biotechnology company, announced significant clinical updates and financial results for the first half of 2025. The company is advancing its drug candidate Namodenoson, which is in a Phase 2a clinical trial for pancreatic cancer and has achieved over 50% enrollment. Namodenoson has received Orphan Drug Designation and FDA approval for compassionate use, sparking interest from U.S. medical centers. Additionally, Can-Fites Piclidenoson has shown promising results in a UCLA study for treating vascular dementia. These developments highlight Can-Fites progress in targeting oncological and inflammatory diseases.
Product Stage
growth-positive
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
Can-Fite BioPharma Ltd., a clinical-stage biotechnology company, announced it has achieved over 50% enrollment in its Phase 2a trial of Namodenoson for pancreatic cancer. The trial is focused on evaluating the safety, clinical activity, and pharmacokinetics of Namodenoson, which has shown a favorable safety profile. Namodenoson is a selective A3 adenosine receptor agonist with demonstrated anti-tumor activity in preclinical models. The drug has received Orphan Drug Designation from the FDA for pancreatic cancer treatment. The milestone reflects strong interest in Namodenoson as a potential treatment for aggressive cancers, and the company remains committed to advancing it as a therapeutic option.
Product Stage
growth-positive
Can-Fite Announces Up To $15.0 Million Public Offering
Can-Fite BioPharma Ltd., a clinical-stage biotechnology company, announced the pricing of a public offering involving 8,333,333 American Depositary Shares (ADSs) and short-term warrants to purchase up to 16,666,666 ADSs. The offering, managed by H.C. Wainwright & Co., is expected to generate approximately $5.0 million in gross proceeds, with an additional potential of $10.0 million from warrant exercises. The funds will be used for research, development, clinical trials, and general corporate purposes. The offering is set to close around July 29, 2025, and is conducted under a registration statement declared effective by the SEC.
PIPE/PO
growth-positive
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
Can-Fite BioPharma Ltd., a clinical-stage biotechnology company, announced promising results from a study conducted by UCLA on their drug Piclidenoson. The study demonstrated the drugs efficacy in a vascular dementia model, showing potential to restore tissue integrity and behavioral function. Vascular dementia, a major cause of dementia, currently lacks FDA-approved treatments. Piclidenoson, a selective A3 adenosine receptor agonist, has shown safety and anti-inflammatory activity in previous trials. With the global vascular dementia market estimated at $6 billion, Piclidenoson could address a significant unmet need. Can-Fite is also advancing other drug candidates, including Namodenoson, which has received Orphan Drug and Fast Track Designations for hepatocellular carcinoma.
Product StageFDA approved/pending approval
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $98.45M |
| Last funding | $3M |
| Stage | Public |
| Rounds | 19 |
| Investors | 2 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | www.canfite.com |
Locations
Bareket St 10, Petah Tikva, Israel
255 Bear Hill Road, Waltham, MA, USA
Photos & Videos
1 item(s)
Can-Fite BioPharma Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersLife SciencesPharmaceuticalsCore Technology
BiologicalsMoleculesTags (15)
oncologycancerinflammatory-diseasesorphan-drugpharmaceuticalsautoimmune-diseasesbiopharmaceuticalmetabolic-diseasedoctorsdrug-discoverypharma-companiespatientsbiotechnologydrug-developmenthospitalsGeographic Markets
GlobalCan-Fite BioPharma Financials
$98.45M
Total funding
Undisclosed
Capital raised
$3M
Last funding
Public
Funding stage
19
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$3.2MApr 2019
$4.2MApr 2019
$7.2MApr 2025
$17.2MAug 2021
$22.2MAug 2024
$30.2MDec 2014
$37.4MFeb 2013
$42.4MFeb 2020
$47.4MJan 2017
$49.8MJan 2019
$57.3MJan 2023
$60.6MJul 2020
$68.7MJun 2020
$73.7MMar 2014
$78.7MMar 2018
$84.7MMay 2019
$89.5MOct 2015
$98.5MSep 2015
Private Equity Funding
PIPE
Apr 2025
$3M
PIPE
Aug 2024
$5M
PIPE
Jan 2023
$7.5M
Undisclosed Investor(s)
PIPE
Aug 2021
$10M
Undisclosed Investor(s)
PIPE
Jul 2020
$3.4M
Undisclosed Investor(s)
PIPE
Jun 2020
$8M
Undisclosed Investor(s)
PIPE
Feb 2020
$5M
Undisclosed Investor(s)
PIPE
May 2019
$6M
Undisclosed Investor(s)
PIPE
Apr 2019
$3.2M
Undisclosed Investor(s)
PIPE
Apr 2019
$1M
CKD Pharmaceuticals
PIPE
Jan 2019
$2.35M
Undisclosed Investor(s)
PIPE
Mar 2018
$5M
Undisclosed Investor(s)
PIPE
Jan 2017
$5M
Undisclosed Investor(s)
PIPE
Oct 2015
$4.8M
Undisclosed Investor(s)
PIPE
Sep 2015
$9M
Undisclosed Investor(s)
PIPE
Dec 2014
$8M
Undisclosed Investor(s)
PIPE
Mar 2014
$5M
Undisclosed Investor(s)
PIPE
Feb 2013
$7.2M
Public Offering / Exit
POEvent
Sep 2005
Undisclosed
Can-Fite BioPharma Lifecycle
Cumulative Funding Raised Over Time
$3.2MApr 2019
$4.2MApr 2019
$7.2MApr 2025
$17.2MAug 2021
$22.2MAug 2024
$30.2MDec 2014
$37.4MFeb 2013
$42.4MFeb 2020
$47.4MJan 2017
$49.8MJan 2019
$57.3MJan 2023
$60.6MJul 2020
$68.7MJun 2020
$73.7MMar 2014
$78.7MMar 2018
$84.7MMay 2019
$89.5MOct 2015
$98.5MSep 2015
All Events
PIPE
Apr 2025
$3M
PIPE
Aug 2024
$5M
PIPE
Jan 2023
$7.5M
Undisclosed Investor(s)
PIPE
Aug 2021
$10M
Undisclosed Investor(s)
PIPE
Jul 2020
$3.4M
Undisclosed Investor(s)
PIPE
Jun 2020
$8M
Undisclosed Investor(s)
PIPE
Feb 2020
$5M
Undisclosed Investor(s)
PIPE
May 2019
$6M
Undisclosed Investor(s)
PIPE
Apr 2019
$3.2M
Undisclosed Investor(s)
PIPE
Apr 2019
$1M
CKD Pharmaceuticals
PIPE
Jan 2019
$2.35M
Undisclosed Investor(s)
PIPE
Mar 2018
$5M
Undisclosed Investor(s)
PIPE
Jan 2017
$5M
Undisclosed Investor(s)
PIPE
Oct 2015
$4.8M
Undisclosed Investor(s)
PIPE
Sep 2015
$9M
Undisclosed Investor(s)
PIPE
Dec 2014
$8M
Undisclosed Investor(s)
PIPE
Mar 2014
$5M
Undisclosed Investor(s)
PIPE
Feb 2013
$7.2M
POEvent
Sep 2005
Undisclosed
Can-Fite BioPharma News
185 articles
growth-positive
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
Can-Fite BioPharma Ltd., a biotechnology company, announced a significant clinical finding under its compassionate use program for Namodenoson, a drug targeting oncological and inflammatory diseases. A patient with decompensated liver cirrhosis showed complete resolution of esophageal varices, a severe complication of advanced liver disease, after treatment with Namodenoson. This outcome suggests a potential disease-modifying effect of the drug. Namodenoson is currently in a Phase III clinical trial for hepatocellular carcinoma and other trials for different conditions. The findings may provide valuable insights for its ongoing development. The U.S. market for liver cirrhosis treatment is expected to grow significantly by 2030.
Product Stage
growth-positive
Can-Fite Reports H1 2025 Financial Results and Clinical Update
Can-Fite BioPharma Ltd., a biotechnology company, announced significant clinical updates and financial results for the first half of 2025. The company is advancing its drug candidate Namodenoson, which is in a Phase 2a clinical trial for pancreatic cancer and has achieved over 50% enrollment. Namodenoson has received Orphan Drug Designation and FDA approval for compassionate use, sparking interest from U.S. medical centers. Additionally, Can-Fites Piclidenoson has shown promising results in a UCLA study for treating vascular dementia. These developments highlight Can-Fites progress in targeting oncological and inflammatory diseases.
Product Stage
growth-positive
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
Can-Fite BioPharma Ltd., a clinical-stage biotechnology company, announced it has achieved over 50% enrollment in its Phase 2a trial of Namodenoson for pancreatic cancer. The trial is focused on evaluating the safety, clinical activity, and pharmacokinetics of Namodenoson, which has shown a favorable safety profile. Namodenoson is a selective A3 adenosine receptor agonist with demonstrated anti-tumor activity in preclinical models. The drug has received Orphan Drug Designation from the FDA for pancreatic cancer treatment. The milestone reflects strong interest in Namodenoson as a potential treatment for aggressive cancers, and the company remains committed to advancing it as a therapeutic option.
Product Stage
growth-positive
Can-Fite Announces Up To $15.0 Million Public Offering
Can-Fite BioPharma Ltd., a clinical-stage biotechnology company, announced the pricing of a public offering involving 8,333,333 American Depositary Shares (ADSs) and short-term warrants to purchase up to 16,666,666 ADSs. The offering, managed by H.C. Wainwright & Co., is expected to generate approximately $5.0 million in gross proceeds, with an additional potential of $10.0 million from warrant exercises. The funds will be used for research, development, clinical trials, and general corporate purposes. The offering is set to close around July 29, 2025, and is conducted under a registration statement declared effective by the SEC.
PIPE/PO
growth-positive
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
Can-Fite BioPharma Ltd., a clinical-stage biotechnology company, announced promising results from a study conducted by UCLA on their drug Piclidenoson. The study demonstrated the drugs efficacy in a vascular dementia model, showing potential to restore tissue integrity and behavioral function. Vascular dementia, a major cause of dementia, currently lacks FDA-approved treatments. Piclidenoson, a selective A3 adenosine receptor agonist, has shown safety and anti-inflammatory activity in previous trials. With the global vascular dementia market estimated at $6 billion, Piclidenoson could address a significant unmet need. Can-Fite is also advancing other drug candidates, including Namodenoson, which has received Orphan Drug and Fast Track Designations for hepatocellular carcinoma.
Product StageFDA approved/pending approval
growth-positive
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
Can-Fite BioPharma Ltd., a clinical-stage biotechnology company, announced progress in its Phase IIa clinical trial of Namodenoson for advanced pancreatic cancer. The trial, which has enrolled 50% of its planned cohort, is assessing the safety and clinical activity of Namodenoson. The drug has been granted Orphan Drug Designation by the FDA. Can-Fite aims to engage with potential partners at the 2025 BIO International Convention to further its clinical pipeline. The company is also advancing other drug candidates for various conditions, including psoriasis and hepatocellular carcinoma, with Namodenoson showing potential for treating multiple cancers.
Product StagePartners
growth-positive
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
Can-Fite BioPharma Ltd., a biotechnology company, has raised $175 million in funding to advance its drug candidates, Namodenoson and Piclidenoson, into pivotal Phase III studies for liver cancer and psoriasis. The company is recognized for developing small-molecule therapeutics targeting the A3 adenosine receptor. Namodenoson is in a Phase III study for advanced liver cancer and a Phase IIa study for pancreatic cancer, while Piclidenoson is in a Phase III trial for psoriasis. Can-Fite has signed seven commercialization agreements with strategic partners and continues to seek additional partnerships. The funding supports drug manufacturing, regulatory activities, and intellectual property protection. Namodenoson has received Orphan Drug and Fast Track Designations from the FDA.
InvestmentProduct StagePartners
growth-positive
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Can-Fite BioPharma Ltd., a biotechnology company, has announced that its oncological drug Namodenoson has received FDA approval for compassionate use in treating pancreatic carcinoma. This marks a significant milestone in its clinical journey, sparking interest from U.S. medical centers to treat patients under compassionate use protocols. The company is also enrolling patients in Israel for a Phase IIa study to assess the safety and efficacy of Namodenoson in advanced pancreatic adenocarcinoma. Namodenoson has been granted Orphan Drug Designation by the U.S. FDA, highlighting its potential as a promising therapeutic option. Can-Fite is an advanced clinical stage drug development company with a focus on cancer, liver, and inflammatory diseases.
Product StageFDA approved/pending approval
growth-positive
Can-Fite Reports 2024 Financial Results and Clinical Update
Can-Fite BioPharma Ltd., a biotechnology company, announced significant clinical updates and financial results for 2024. Their drug candidate, Namodenoson, has shown promising results in treating liver cancer, with a patient achieving an 8-year cancer-free survival. Namodenoson also demonstrated protective effects across multiple body systems, distinguishing it from conventional chemotherapy. The drug has been granted Orphan Drug Designation by the FDA for pancreatic cancer, offering potential market exclusivity and regulatory advantages. A Phase IIa clinical trial has been initiated for patients with advanced pancreatic adenocarcinoma. The FDA approved compassionate use treatment for a U.S.-based pancreatic cancer patient with Namodenoson.
Product StageFDA approved/pending approval
growth-positive
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
Can-Fite BioPharma Ltd., a biotechnology company, has completed an analysis of its partnerships and market potential for its lead drug candidates, Piclidenoson and Namodenoson. The company anticipates substantial revenue generation over the next decade, contingent on regulatory approvals and market launches between 2027 and 2029. Can-Fites partnerships include diverse financial components, such as development milestones and royalties. The company is in advanced clinical stages, with Piclidenoson in a Phase III trial for psoriasis and Namodenoson in trials for liver cancer, MASH, and pancreatic cancer. Namodenoson has received Orphan Drug and Fast Track Designations. The companys strategic collaborations and clinical progress underscore its potential for long-term growth.
Product StagePartners
growth-positive
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
Can-Fite BioPharma Ltd., a biotechnology company, has announced a registered direct offering of 2,500,000 American Depositary Shares (ADSs) at $1.20 per ADS, expected to raise $3.0 million. The offering, facilitated by H.C. Wainwright & Co. as the exclusive placement agent, is set to close on April 15, 2025. The funds will be used for research, development, clinical trials, and general corporate purposes. Can-Fite is advancing its drug candidates, including Piclidenoson and Namodenoson, which are in various phases of clinical trials targeting cancer and inflammatory diseases. Namodenoson has received Orphan Drug and Fast Track Designations from the FDA. The company is leveraging its platform technology to address significant markets in oncology and liver diseases.
PIPE/PO
growth-positive
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
bioAffinity Technologies, Inc. is featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, highlighting its product CyPath® Lung, which is designed for early-stage lung cancer diagnosis. The company has secured a U.S. Federal Supply Schedule contract, making the test available to U.S. veterans and federal health service patients, which is expected to boost sales growth. The product is marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services, a subsidiary of bioAffinity. This development is seen as growth-positive for the company, as it addresses a critical need in noninvasive cancer diagnosis.
Product StageCustomers
growth-positive
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
Can-Fite BioPharma Ltd., a biotechnology company, has initiated a pivotal Phase 3 clinical trial for its oral drug Piclidenoson, targeting moderate to severe plaque psoriasis. The trial, approved by the FDA and EMA, will enroll patients in Europe, with the US and Canada to follow. The study aims to demonstrate the drugs safety and efficacy, with primary objectives including achieving a PASI 75 score and a sPGA of 0 or 1 at Week 16. The FDA has requested two Phase 3 studies and encouraged the inclusion of adolescent patients. Upon successful completion, Can-Fite plans to submit an NDA to the FDA and an MAA to the EMA.
Product Stage
growth-positive
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
Can-Fite BioPharma Ltd., a biotechnology company, is advancing its veterinary drug Piclidenoson, targeting canine osteoarthritis. Partnering with Vetbiolix, the company is conducting advanced clinical trials. The veterinary market for osteoarthritis is projected to grow significantly, and Can-Fite anticipates capturing a portion of this market, with potential peak sales of $445 million by 2034. The company expects to earn $325 million in royalties over the next decade, assuming a 2029 launch. Piclidenoson offers a safer alternative to current treatments, which have significant side effects. This development represents a significant growth opportunity for Can-Fite in the veterinary sector.
Product StagePartners
growth-positive
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
Can-Fite BioPharma Ltd. is advancing its clinical development of Piclidenoson for Lowe Syndrome, a rare genetic disease. The company has completed the Phase II design and is preparing for a clinical study involving 5 patients. This study will assess the efficacy of Piclidenoson in increasing renal uptake. The study is backed by successful pre-clinical work and a collaboration with Fondazione Telethon. Lowe Syndrome is a rare, X-linked genetic condition affecting males, characterized by vision, kidney, and brain issues. The collaboration aims to address this high medical need, as no current treatments exist. The studys principal investigator is Dr. Franchesca Emma from Bambino Gesù Childrens Hospital in Rome.
Product StagePartners
growth-positive
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
Can-Fite BioPharma Ltd., a biotechnology company, announced that it received FDA approval for the compassionate use of its anti-cancer drug Namodenoson for a U.S. pancreatic cancer patient. Namodenoson is currently in a Phase IIa clinical trial for pancreatic cancer and a Phase III trial for liver cancer. The drug has been granted Orphan Drug Designation by the FDA, which provides potential market exclusivity and regulatory advantages. Namodenoson targets the A3 adenosine receptor and is being evaluated for various cancers. The company is advancing its drug pipeline, including Piclidenoson and CF602, for other diseases.
FDA approved/pending approval
growth-positive
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
Can-Fite BioPharma Ltd. announced the publication of a study in the European Society of Medicine Journal highlighting the protective effects of its drug Namodenoson. The study, a collaboration with Soroka University Medical Center, demonstrates Namodenosons anti-ischemic, anti-inflammatory, anti-fibrotic, and anti-toxicity effects. Namodenoson is being evaluated in a pivotal Phase III trial for advanced liver cancer, with FDA and EMA approval, and holds Orphan Drug and Fast Track status. The drugs unique profile as an anti-cancer therapy that protects healthy tissues positions it as a potential breakthrough in oncology.
Product StageFDA approved/pending approval
growth-positive
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
Can-Fite BioPharma Ltd. announced promising clinical results for its drug Namodenoson, used under a compassionate use program for treating decompensated liver cirrhosis. The treatment has shown significant improvements in patient symptoms, such as reduced fatigue, edema, and liver stiffness, with no further episodes of gastrointestinal bleeding. This development is significant given the limited treatment options available for advanced liver disease, which often requires liver transplantation. The U.S. market for liver cirrhosis treatment is projected to reach $15 billion by 2030, highlighting the potential impact of Namodenoson as a treatment option. The positive response to the drug could provide a much-needed alternative for patients awaiting liver transplants.
Product Stage
growth-positive
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25
Can-Fite BioPharma Ltd., a biotechnology company, is advancing its pipeline of small molecule drugs targeting oncological and inflammatory diseases. The company is hosting a webinar on February 25, 2025, to discuss its development pipeline and upcoming milestones. Can-Fite has secured over $20 million in upfront and milestone payments, with potential regulatory and sales milestone payments exceeding $130 million. The company is in advanced clinical stages with its lead drug candidates, Piclidenoson and Namodenoson, targeting large markets. Namodenoson has received Orphan Drug and Fast Track Designations in the U.S. and Europe. The company is well-positioned for potential commercialization of its therapies.
Product StageInvestment
growth-positive
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
Can-Fite BioPharma Ltd., a biotechnology company, is set to present at the BIO CEO & Investor Conference in New York City on February 10-11, 2025. The company will discuss its business strategy, recent clinical milestones, and future development plans with investors and potential partners. Can-Fite is advancing its pipeline of small molecule drugs targeting oncological and inflammatory diseases. Its lead drug candidate, Namodenoson, is in pivotal Phase III trials for liver cancer and Phase IIb for MASH. Another candidate, Piclidenoson, is preparing for a Phase III trial for psoriasis. Namodenoson has received Orphan Drug and Fast Track Designations from the FDA. Can-Fites drugs have shown efficacy and safety in over 1,600 patients.
Product StagePartners
growth-positive
Can-Fite BioPharma secures US patent for Namodenoson
Can-Fite BioPharma has secured a US patent for its lead drug candidate, Namodenoson, for use as an anti-obesity treatment. The patent, set to be issued in February 2025 and expiring in 2042, covers the oral administration of the drug to reduce fat levels and body weight. Namodenoson is currently in a Phase IIb study for treating metabolic dysfunction-associated steatohepatitis (MASH), with promising results in reducing body weight and increasing adiponectin levels. The drug has shown a favorable safety profile and has received orphan drug status in the US and Europe, as well as fast-track designation from the FDA for hepatocellular carcinoma treatment.
Product Stage
growth-positive
US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
Can-Fite BioPharma Ltd. has announced that its lead drug candidate, Namodenoson, has been granted a patent by the US Patent Office for its use as an anti-obesity drug. The patent, which will be issued on February 2nd and expires in 2042, covers methods of treating obesity by administering Namodenoson orally. Namodenoson is currently in clinical trials for various conditions, including Metabolic Dysfunction-associated Steatohepatitis (MASH) and advanced liver cancer. The drug has shown a favorable safety profile and effectiveness in reducing fat levels and body weight in preclinical studies. This patent approval positions Can-Fite well in the growing obesity treatment market, which is expected to reach $60.5 billion by 2030.
Product Stage
growth-positive
CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know
Can-Fite Biopharma Ltd has received a Zacks Rank #1 (Strong Buy) upgrade, indicating a positive outlook on its earnings estimates. This upgrade is based on an upward trend in earnings estimates, which is a significant factor influencing stock prices. The Zacks rating system, which is highly regarded for its correlation with near-term stock movements, suggests that Can-Fites improved earnings outlook could lead to increased buying pressure and a rise in its stock price. The article emphasizes the importance of tracking earnings estimate revisions for making informed investment decisions.
growth-positive
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Can-Fite BioPharma Ltd., a biotechnology company, is advancing its drug candidate Namodenoson, which will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium. Namodenoson is currently in a pivotal Phase III trial for advanced liver cancer treatment. The drug has shown promising results, including completely clearing cancer in a Phase IIb trial patient who remains cancer-free for over eight years. Namodenoson is unique due to its liver-protective effects, mediated via adiponectin, offering a safer alternative to existing treatments that induce liver toxicity. The drugs safety profile and efficacy have garnered significant recognition in the scientific community, and Can-Fite is hopeful it will prolong life for advanced liver cancer patients.
growth-positive
Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now
Can-Fite Biopharma Ltd (CANF) has experienced a 26.8% decline in its stock over the past week. However, a hammer chart pattern formed in its last trading session suggests a potential trend reversal, indicating that the stock may have found support. This pattern, combined with strong agreement among Wall Street analysts in raising earnings estimates, enhances the prospects of a trend reversal. The consensus EPS estimate for the current year has increased by 3.1% over the last 30 days, reflecting analysts confidence in the companys potential to report better earnings. The hammer pattern is a technical indicator used to identify potential reversals, and its occurrence at the bottom of a downtrend signals that the bears might have lost control over the price.
growth-positive
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
Can-Fite BioPharma Ltd., a biotechnology company, announced a significant milestone in its Phase II Liver Cancer Study involving the drug Namodenoson. A patient treated with Namodenoson has achieved an overall survival time of 8 years with a complete response, showcasing the drugs potential in treating advanced liver cancer. Can-Fite is currently enrolling patients for a pivotal Phase III clinical study in Israel, Europe, and the US, with the study protocol approved by the FDA and EMA. Namodenoson has been granted Orphan Drug and Fast Track Status by the FDA, highlighting its promise in treating hepatocellular carcinoma (HCC). The market for HCC treatments is projected to reach $6.1 billion by 2027. The article emphasizes Namodenosons unique ability to target tumor cells while protecting normal liver cells.
Customers
growth-positive
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
60 Degrees Pharmaceuticals, Inc. and Can-Fite BioPharma Ltd. are featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Geoffrey Dow, CEO of 60 Degrees Pharmaceuticals, discusses the companys mission to develop therapies for infectious diseases, highlighting their FDA-approved antimalarial drug ARAKODA® and plans to expand its indications. The company collaborates with research organizations in the U.S., Australia, and Singapore, supported by in-kind funding from the U.S. Department of Defense and private investors like Knight Therapeutics Inc. Motti Farbstein, CEO of Can-Fite, discusses their clinical-stage drug development efforts in oncology and inflammatory diseases, emphasizing the potential impact on patient care and upcoming milestone payments.
CustomersPartners
growth-positive
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
Can-Fite BioPharma Ltd., a biotechnology company, has announced the dosing of the first patient in a Phase IIa clinical trial for Namodenoson, targeting advanced pancreatic adenocarcinoma. The trial aims to evaluate the safety and efficacy of Namodenoson, which has recently received Orphan Drug Designation from the US FDA. This designation is significant as it provides certain benefits and incentives for the company. The trial involves approximately 20 patients and is being conducted in multiple centers, including the Rabin Medical Center in Israel and UT Southwestern Medical Center in the US. The primary objective is to assess the safety profile, while secondary objectives include evaluating clinical activity and survival rates.
growth-positive
Can-Fite BioPharma Secures Australian Patent for Obesity Drug
Can-Fite BioPharma Ltd. has secured a patent allowance in Australia for its oral anti-obesity drug, Namodenoson. This patent, which is valid until 2040, covers methods of treating obesity by increasing adiponectin hormone levels to reduce body fat. The approval positions Can-Fite BioPharma in the global obesity treatment market, which is valued at $12 billion as of 2023. The patent is expected to enhance the companys market presence and potential growth in the obesity treatment sector.
growth-positive
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Can-Fite BioPharma Ltd. announced that its patent application for Namodenoson, a drug targeting obesity, has been accepted by the Australian Patent Office. The patent, valid until 2040, covers the use of Namodenoson for fat loss by increasing adiponectin levels. Namodenoson has shown a favorable safety profile and is being developed for treating MASH, advanced liver cancer, and pancreatic cancer. The drug demonstrated a 2.3% weight loss in a Phase IIa study with MASH patients. Can-Fite is optimistic about the drugs potential in the lucrative global obesity treatment market, valued at USD 12 billion in 2023. The company is conducting further clinical trials to explore Namodenosons efficacy in treating various conditions.
growth-positive
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
Can-Fite BioPharma Ltd., a biotechnology company, announced positive results from a clinical study on dogs with osteoarthritis using their drug Piclidenoson. Their veterinary partner, Vetbiolix, has exercised an option for a full in-license agreement, which could yield Can-Fite up to $325 million over the next decade. The study demonstrated significant improvement in dogs clinical status and pain reduction. This partnership with Vetbiolix, which covers all veterinary clinical development costs, is expected to accelerate Piclidenosons market entry and contribute to Can-Fites near-term revenues. The canine osteoarthritis market is projected to reach $3 billion by 2028, highlighting the potential for growth in this sector.
Partners
growth-positive
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
Can-Fite BioPharma Ltd., a biotechnology company, announced that its oncology drug candidate, Namodenoson, has been granted Orphan Drug Designation by the U.S. FDA for pancreatic cancer. This designation provides potential market exclusivity for seven years post-approval and other regulatory advantages. The company is preparing for a Phase II study to evaluate the safety and clinical activity of Namodenoson in patients with advanced pancreatic adenocarcinoma. The study aims to start by the end of the year and will involve approximately 20 patients. Namodenoson has shown promise in treating various cancers and has an excellent safety profile. The designation is expected to positively impact Can-Fites growth by enhancing its market position and advancing its drug development efforts.
growth-positive
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
Can-Fite BioPharma Ltd., a biotechnology company, is advancing its pipeline of small molecule drugs targeting oncological and inflammatory diseases. The company has secured over $450 million in potential milestone payments from out-licensing deals, with $20 million already received. Can-Fites lead drug candidate, Piclidenoson, is progressing to a pivotal Phase III trial for psoriasis. Another drug, Namodenoson, is in Phase IIb and Phase III trials for MASH and hepatocellular carcinoma, respectively, and has received Orphan Drug and Fast Track Designations. The company plans a Phase IIa study for pancreatic cancer. Can-Fite will host a webinar on October 29, 2024, to discuss its development pipeline and milestones.
growth-positive
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
Can-Fite BioPharma Ltd. announced a development and commercialization agreement with its veterinary partner Vetbiolix for the drug Piclidenoson, aimed at treating osteoarthritis in companion animals. This agreement follows a successful clinical study in dogs. The arthritis market for companion animals is projected to grow significantly, and Can-Fite expects to capture a portion of this market, with potential peak worldwide sales of $445 million by 2034. Can-Fite will receive a 15% royalty on worldwide sales, projected to be $325 million over the next decade. This partnership highlights the potential for milestone and royalty revenues for Can-Fite.
Partners
growth-positive
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
Can-Fite BioPharma Ltd. announced that it has received approval from the Israeli Ministry of Health to conduct a Phase IIa clinical trial for Namodenoson in the treatment of pancreatic carcinoma. The trial aims to establish the safety and clinical efficacy of the drug in patients with advanced pancreatic adenocarcinoma. Approximately 20 patients will be enrolled in this multicenter open-label trial. The primary objective is to characterize the safety profile of Namodenoson, while the secondary objective is to evaluate its clinical activity. The study will be conducted by leading oncologists in Israel and the US.
Customers
growth-positive
Is Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts?
Can-Fite BioPharma Ltd. (NYSE:CANF) is highlighted as a promising penny stock with an upside potential of 317% and an average analyst price target of $10. The company focuses on innovative treatments for cancer, liver and inflammatory diseases, and erectile dysfunction. Key drug candidates, Piclidenoson and Namodenoson, are advancing through crucial clinical stages. Strategic partnerships, such as Ewopharmas distribution agreement for pancreatic cancer, and recent patent allowances bolster the companys growth prospects. Financially, Can-Fite has reduced its net loss and maintains a strong cash position. Overall, the company is well-positioned for growth in the biopharmaceutical sector.
Partners
growth-positive
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
Can-Fite BioPharma Ltd. announced its financial results and clinical updates for the first half of 2024. The company raised approximately $5 million through the exercise of warrants. Positive clinical results were reported for its drug candidate Piclidenoson in a study conducted by partner Vetbiolix. The company is advancing its Namodenoson drug candidate through various clinical trials for liver cancer, pancreatic cancer, and MASH. Financially, the company reported a decrease in revenues and net loss compared to the same period in 2023. Can-Fite continues to position its drugs for multi-billion dollar markets with unmet needs.
InvestmentPartnersCustomers
growth-positive
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
RedChip Companies will air interviews with OS Therapies Inc. and Can-Fite BioPharma Ltd. on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. OS Therapies is developing novel treatments for Osteosarcoma and other solid tumors, and is on the verge of major clinical milestones. Can-Fite BioPharma is an advanced clinical stage drug development company with a platform of oral drugs designed to address multi-billion-dollar markets in the treatment of oncology and inflammatory diseases. The Company has two drug candidates in advanced stages of development, Piclidenoson for the treatment of psoriasis and Namodenoson for the treatment of advanced liver cancer.
CustomersPartnersExpand
growth-positive
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
Can-Fite BioPharma Ltd. has announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,857,143 American Depositary Shares (ADSs). In consideration for the immediate exercise of the warrants for cash, Can-Fite will issue new unregistered warrants to purchase up to 5,714,286 ADSs. The gross proceeds to Can-Fite from the exercise of the warrants are expected to be approximately $5.0 million. The Company intends to use the net proceeds for funding research and development and clinical trials and for other working capital and general corporate purposes.
Investment
growth-positive
Can-Fite Provides Namodenoson Patent Update
Can-Fite BioPharma Ltd. has announced an update on the intellectual property status of its lead drug candidate, Namodenoson. The drug, which is being developed for advanced liver cancer, pancreatic cancer, and MASH, has patents and patent applications that cover methods of treating liver and pancreatic carcinoma. A patent application for the manufacturing of the drug has also been filed. The patents and patent applications will have expiration dates of 2044 and beyond. Can-Fite is currently conducting a Phase III study in advanced liver cancer and a Phase IIb study in MASH.
InvestmentExpand
growth-positive
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
Can-Fite BioPharma Ltd., a biotechnology company, is inviting investors to a webinar on August 8, 2024, to discuss its current development pipeline and upcoming milestones. The company, which is advancing a pipeline of proprietary small molecule drugs addressing oncological and inflammatory diseases, has received $20 million in upfront and milestone payments and has potential milestone payments totaling over $130 million. The companys lead drug candidate, Piclidenoson, recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III.
Investment
growth-positive
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
Can-Fite BioPharma Ltd., a biotechnology company, has submitted an application to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its drug candidate Namodenoson in the treatment of pancreatic carcinoma. The company plans to start a Phase IIa clinical study soon. The Orphan Drug application for Namodenoson underscores the high unmet medical need for a safe and efficacious drug for this devastating disease. The application further validates the belief that Namodenoson may potentially offer efficacy on top of the drug safety that has been already proved in other clinical indications.
InvestmentExpand
growth-positive
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
Can-Fite BioPharma Ltd. has announced that a patient with liver decompensated cirrhosis showed an improvement in liver indices after being treated with Namodenoson under compassionate use at the Soroka Medical Center in Israel. Namodenoson is currently used in a pivotal Phase III study for patients with advanced liver cancer and a Phase IIb study for MASH (metabolic dysfunction-associated steatohepatitis). The global market for liver cirrhosis treatment is estimated to reach $29.2 billion by 2030.
InvestmentExpand
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
growth-positive
Can-Fite receives FDA IND clearance for Phase IIb MASH treatment trial
Can-Fite BioPharma has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for a Phase IIb clinical trial of Namodenoson to treat metabolic dysfunction-associated steatohepatitis (MASH). The company is actively enrolling patients for the trial in Europe, Israel, and now the US. The trial will assess the efficacy of Namodenoson versus placebo in 140 MASH patients. The companys CEO, Motti Farbstein, expressed hope that recruitment will be completed in the next few months.
InvestmentExpand
growth-positive
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Can-Fite BioPharma and Nutriband Inc. will be featured in interviews on the RedChip Small Stocks, Big Money show on Bloomberg TV. Can-Fite BioPharma is developing oral drugs for oncology and inflammatory diseases, with two drug candidates in advanced stages of development. Nutriband is addressing the global opioid crisis with its AVERSA abuse-deterrent transdermal technology. The interviews will provide corporate updates from both companies.
CustomersPartners
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
Growth-Positive
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
Planet MicroCap is hosting the Planet MicroCap Showcase: VEGAS from April 30 to May 2, 2024. The event will feature 96 MicroCap public and private companies presenting at the Paris Hotel & Casino in Las Vegas, NV. The showcase will begin with a MicroCap Investing Workshop featuring financial influencers, investors, fund managers, and key opinion leaders. The following day will consist of company presentations, and the final day will be dedicated to 1x1 meetings. Companies interested in presenting can register for the event online.
Customers
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
growth-positive
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
Can-Fite BioPharma, Ltd. announced it will be presenting at The 14th Annual LD Micro Invitational in New York on April 8th-9th, 2024. The company is an advanced clinical stage drug development company with a platform technology designed to address markets in the treatment of cancer, liver, and inflammatory disease. Its lead drug candidate, Piclidenoson, recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite’s cancer and liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of steatotic liver disease (SLD), a Phase III pivotal trial for hepatocellular carcinoma (HCC), and the company is planning a Phase IIa study in pancreatic cancer.
Investment
Can-Fite Reports 2023 Financial Results and Clinical Update
Can-Fite Reports 2023 Financial Results and Clinical Update
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
growth-positive
Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson
Can-Fite BioPharma Ltd. has reported positive results from a patient treated with namodenoson in its phase II liver cancer study. The patient, suffering from advanced hepatocellular carcinoma (HCC), showed a complete response and overall survival of 6.9 years. The companys stock rose 6.7% following the announcement, despite a year-to-date decline of 65.1%. Can-Fite is currently enrolling patients for a phase III study of namodenoson for the treatment of advanced HCC. The drug has been granted Orphan Drug and Fast Track status by the FDA.
Investment
growth-positive
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
Can-Fite BioPharma Ltd. has entered into an agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,963,637 American Depositary Shares (ADSs). The company will issue new unregistered warrants to purchase up to 3,927,274 ADSs. The gross proceeds from the exercise of the warrants are expected to be approximately $3.0 million, which will be used for funding research and development, clinical trials, and other working capital and general corporate purposes. The closing of the offering is expected to occur on or about November 24, 2023.
Investment
Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
growth-positive
Can-Fite Biopharma Ltd (CANF) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Can-Fite Biopharma Ltd (CANF) has been experiencing a downtrend, with the stock losing 6.6% over the past week. However, a hammer chart pattern formed in its last trading session, indicating a potential trend reversal. This pattern, along with rising optimism among Wall Street analysts about the companys future earnings, suggests that the stock could find support. Over the last 30 days, the consensus EPS estimate for the current year has increased by 25.3%. CANF currently has a Zacks Rank #1 (Strong Buy), indicating it is in the top 5% of more than 4,000 stocks ranked based on trends in earnings estimate revisions and EPS surprises.
Investment
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
growth-positive
Best Momentum Stocks to Buy for October 27th
Three companies, Vertiv Holdings Co, The Progressive Corporation, and Can-Fite BioPharma Ltd, are highlighted for their strong momentum characteristics and buy rank. Vertiv Holdings Co, a digital infrastructure solutions provider, has seen its shares gain 34.3% over the last three months. The Progressive Corporation, an insurance holding company, has seen its shares gain 23.1% over the same period. Can-Fite BioPharma Ltd, a biopharmaceutical company, has seen its shares gain 9.2% over the last six months. All three companies have a Zacks Rank #1 and have seen the Zacks Consensus Estimate for their current year earnings increase.
Investment
growth-positive
New Strong Buy Stocks for October 27th
Five companies have been added to the Zacks Rank #1 (Strong Buy) List. These include Matrix Service Company, an energy infrastructure services company, which has seen its current year earnings estimate increase by 285.7% over the last 60 days. Office Properties Income Trust, a real estate investment trust, has seen its current year earnings estimate increase by 9.2%. Can-Fite BioPharma Ltd, a biopharmaceutical company, has seen its current year earnings estimate increase by 25.3%. Enlivex Therapeutics Ltd, a macrophage reprogramming immunotherapy company, has seen its current year earnings estimate increase by 19.1%. FreightCar America, Inc., a railcar manufacturing company, has seen its current year earnings estimate increase by 13%.
Investment
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
growth-positive
Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
Can-Fite BioPharma Ltd., a biotechnology company developing small molecule drugs for oncology, inflammatory and liver diseases, announced that its CEO, Motti Farbstein, will present at the H.C. Wainwright 25th Annual Conference. Farbstein will discuss Can-Fites advanced stage pipeline, including developments in pancreatic carcinoma and Lowe Syndrome. The companys lead drug candidate, Piclidenoson, recently reported topline results in a Phase 3 trial for psoriasis and is expected to commence a pivotal Phase 3. Can-Fites cancer and liver drug, Namodenoson, is being evaluated in several trials and has been granted Orphan Drug Designation in the U.S. and Europe.
Management Changes
growth-positive
Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
Can-Fite BioPharma Ltd., a biotechnology company, has announced its financial results for the first half of 2023. The company is advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases. It has ongoing studies and is about to commence two more in large treatment markets with unmet needs. The companys revenues for the six months ended June 30, 2023 were $0.39 million, compared to revenues of $0.41 million during the same period in 2022. As of June 30, 2023, Can-Fite had cash and cash equivalents and short term deposits of $9.60 million.
CustomersPartners
growth-positive
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
Can-Fite BioPharma has signed an agreement with Fondazione Telethon for the co-development of Piclidenoson for the treatment of Lowe Syndrome. The collaboration aims to address the high medical need for a treatment for Lowe Syndrome, a rare genetic disease with no available drug. Can-Fite estimates the total addressable market for the treatment of Lowe Syndrome to be approximately $100 million in the U.S. alone. The company plans to move into an advanced stage clinical study for Piclidenoson, which may open a path to approval. The treatment may qualify for Orphan Drug Designation by the FDA and EMA, granting special development status. Can-Fite is hopeful that Piclidenoson can offer a much-needed treatment for infants, children, and young people living with Lowe Syndrome.
Partners
growth-positive
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
Can-Fite BioPharma has submitted a pediatric study plan to the FDA for the treatment of adolescents with psoriasis using Piclidenoson. The plan aims to enroll adolescents in the companys upcoming Phase 3 clinical trials for the registration of Piclidenoson as a treatment for plaque psoriasis. Can-Fite believes that including adolescent patients in the trials will broaden the market potential for the drug. The company states that there is a high market need for a safe and effective drug for adolescents with psoriasis, as current treatments have safety issues and are not satisfactory in terms of efficacy. Can-Fites CEO & CFO, Motti Farbstein, believes that Piclidenosons safety profile and effectiveness make it suitable for the chronic treatment of psoriasis in both adults and adolescents.
Customers
Growth-Positive
Presenting on the Emerging Growth Conference on August 9 & 10 Register Now
EmergingGrowth.com, a leading independent small cap media portal, has announced the schedule for the 60th Emerging Growth Conference, which will take place on August 9 and 10, 2023. The conference aims to identify companies in a wide range of growth sectors that have strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth. The conference will feature presentations from a variety of companies, including Longeveron, ASP Isotopes, Alpha Tau Medical, Kintara Therapeutics, Sigyn Therapeutics, and many others.
Partners
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
growth-positive
Presenting on the Emerging Growth Conference on July 12 & 13 Register Now
EmergingGrowth.com, a leading independent small cap media portal, has announced the schedule for its 60th Emerging Growth Conference on July 12 & 13, 2023. The conference identifies companies in a range of growth sectors that have strong management teams, innovative products & services, focused strategy, execution, and the potential for long-term growth. Companies presenting at the conference include Spire Global, Inc., OHB SE, ReWalk Robotics Ltd., SS Innovations International, Inc., GlobeStar Therapeutics Corporation, DBMM Group, Acurx Pharmaceuticals, Inc., Sweet Poison Spirits, Inc., Kodiak Copper Corp., Intellabridge Technology Corporation, dynaCERT Inc., AdAlta, Cerrado Gold, CoTec Holdings Corp., Can-Fite BioPharma Ltd., Bioxytran, RideBay, Inc., Bright Mountain Media, Inc., Scorpio Gold, and Renforth Resources, Inc.
CustomersPartners
growth-positive
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
Can-Fite BioPharma Ltd, a biotechnology company, has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its development and registration plans for Piclidenoson, a drug for treating moderate to severe plaque psoriasis. The FDA has approved the non-clinical studies conducted by Can-Fite and has provided advice on the Phase 3 clinical trial protocol. The FDA has also encouraged Can-Fite to include adolescent patients in their studies due to the drugs strong safety profile. Can-Fite believes this will significantly broaden the market launch potential of the drug.
InvestmentExpand
growth-positive
Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer
Can-Fite BioPharma is making progress in the development of namodenoson, a potential treatment for pancreatic carcinoma. The company is conducting pre-clinical studies and preparing for an investigational new drug (IND) submission to the FDA. The news has had a growth-positive impact on the company, with shares up almost 11.4%. Can-Fite is planning to initiate an open-label phase II exploratory study to assess the safety and efficacy of namodenoson in pancreatic cancer patients. The candidate has shown potential to effectively treat pancreatic carcinoma and has received Orphan Drug Designation and Fast Track Designation. Can-Fite is also developing namodenoson for treating hepatocellular carcinoma and non-alcoholic steatohepatitis. The companys shares have declined 52% year to date.
Customers
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
growth-positive
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
Can-Fite BioPharma Ltd, a biotechnology company, has announced that its study on the effects of Namodenoson on pancreatic carcinoma has been published online in the Journal of Clinical Oncology. The study used advanced pancreatic carcinoma patient cells treated with Namodenoson, both as a stand-alone and in combination with gemcitabine, a leading chemotherapy used to treat pancreatic cancer. The company plans to initiate an open-label Phase 2a exploratory trial to assess the efficacy and safety of Namodenoson in the treatment of patients with pancreatic cancer.
InvestmentExpand
Growth-Positive
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
Can-Fite BioPharma Ltd., a biotechnology company, announced that its VP of Business Development, Dr. Sari Fishman, will participate in BioEquity Europe in Dublin, Ireland from May 14th – 16th, 2023. Dr. Fishman will conduct meetings with potential strategic partners for Can-Fite’s advanced stage pipeline including pharma companies focused on oncology, dermatology, and liver diseases. The company recently announced plans to initiate an open-label Phase 2 exploratory trial to assess the efficacy and safety of Namodenoson in the treatment of patients with pancreatic cancer. The global pancreatic cancer therapeutics market was valued at approximately $3.6 billion in 2021 and is projected to grow to approximately $6.6 billion by 2030.
PartnersExpand
growth-positive
All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy
Can-Fite Biopharma Ltd has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. The Zacks rating system, which tracks EPS estimates, reflects positivity about the companys earnings outlook. Rising earnings estimates and the rating upgrade imply an improvement in Can-Fite Biopharmas underlying business, which could lead to an increase in its stock price. The Zacks Rank stock-rating system, based on earnings estimate revisions, has a strong correlation with near-term stock movements. Can-Fite Biopharma is positioned in the top 20% of Zacks-covered stocks, indicating its superior earnings estimate revision feature.
Investment
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
growth-positive
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
Can-Fite BioPharma Ltd has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the submission of a registration plan for a pivotal Phase III clinical trial for the treatment of moderate to severe psoriasis. The company plans to initiate a prospective double-blind, placebo-controlled and randomized clinical trial with its lead product Piclidenoson. The company is also submitting a comparable data package to the US Food and Drug Administration.
InvestmentExpand
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
growth-positive
Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
Can-Fite BioPharma Ltd. has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson, used in the treatment of moderate to severe psoriasis. The company plans to follow this with a submission to the U.S. Food and Drug Administration (FDA). The registration plans include final efficacy and safety results from Can-Fite’s successful COMFORT™ Phase III study. The company recently reported positive results from this study, which showed significant improvement over placebo in psoriasis patients and an excellent safety profile for Piclidenoson.
InvestmentExpand
Can-Fite Announces ADS Ratio Change
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
growth-positive
Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer
Can-Fite BioPharma Ltd has provided an update on its clinical program for Namodenoson, a treatment for hepatocellular carcinoma (HCC). The company will present the latest data at two upcoming conferences, including findings on a patient who remains cancer-free six years after beginning treatment with Namodenoson. Can-Fites prior Phase 2 study showed that median overall survival in the patient population was 6.8 months for those treated with Namodenoson compared to 4.3 months for those treated with a placebo. A pivotal Phase 3 registration study is open for enrollment of the most advanced liver cancer patients.
Investment
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update
Can-Fite's Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
growth-positive
Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix
Can-Fite BioPharma has announced that its drug, Piclidenoson, will enter a clinical trial for the treatment of osteoarthritis in dogs. This comes as a result of a development and commercialization agreement signed with Vetbiolix in June 2021. Vetbiolix, a France-based veterinary biotech company, has the exclusive right to Piclidenoson in the veterinary osteoarthritis market for companion animals including cats and dogs for two years. If the study yields positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, Vetbiolix will be obligated to pay Can-Fite upfront and milestone payments, in addition to royalties on sales upon regulatory approval.
PartnersCustomers
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
Can-Fite's CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
Can-Fite's Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel Aviv
growth-positive
Liver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
Can-Fite BioPharma Ltd, a biotechnology company, has announced that the last patient treated under an Open Label Extension program of its concluded Phase II study of Namodenoson in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer, experienced a Complete Response (CR) to Can-Fite’s drug. The patient has now survived five years, during which time the clinical benefits of treatment have included the disappearance of ascites, normal liver function, and the disappearance of peritoneal carcinomatosis leading to complete clearance of all cancer lesions. Can-Fite expects to commence patient enrollment in its pivotal Phase III trial for Namodenoson in the first quarter of 2022.
InvestmentExpand
Can-Fite Announces $10.0 Million Registered Direct Offering
Can-Fite's Phase III Psoriasis Study Achieves 75% Enrollment;Top Line Results Expected Q4 2021
Can-Fite Expands its Phase II COVID-19 Study to Europe
Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates
Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
growth-positive
Can-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model
Can-Fite BioPharma Ltd, a biotechnology company, has announced new data from a preclinical study of its drug candidate CF602 in the treatment of erectile dysfunction (ED) in a diabetes experimental model. The study showed that treatment with CF602 resulted in a significant improvement of ED. The company believes that CF602 is an ideal candidate for development due to its proven efficacy in a diabetes pre-clinical model and the massive size of the ED market. The ED therapeutic market is estimated to reach approximately $3.2 billion by 2022.
Investment
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma
Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol
New Positive Data from Can-Fite's Liver Cancer Phase II Clinical Study with Namodenoson
growth-positive
Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies
Can-Fite BioPharma Ltd, a biotechnology company, has completed a set of pre-clinical studies showing that CBD rich T3/C15 cannabis fraction has an inhibitory effect on liver fibrosis. The companys small molecule drug candidate, Namodenoson, has shown efficacy in liver diseases and is headed into a pivotal Phase III in liver cancer and a Phase IIb in NASH. Can-Fite has filed patent applications protecting its discovery of cannabinoid-based treatments where A3AR is overexpressed including liver cancer, other cancers, autoimmune, inflammatory, and metabolic diseases. The medical cannabis market is projected to grow at a CAGR of 29% to $56.7 billion by 2026.
InvestmentExpand
Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal-Cancers
Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs
Can-Fite Reports on Progress With Its Namodenoson NASH Program
Can-Fite's Namodenoson Abstract Selected as 'Best of The Liver Meeting' in the NASH Category of the American Association of Liver Diseases (AASLD)
Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis
FDA Clears Can-Fite to Commence Phase II COVID-19 Study
growth-positive
Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH
Can-Fite BioPharma Ltd, a biotechnology company, has announced that the European Patent Office intends to grant a patent for its invention titled “An A3 Adenosine Receptor For Use In Treating Ectopic Fat Acculturation”. The patent includes the use of the A3 adenosine receptor (A3AR), the target of Can-Fite’s platform technology, in reducing ectopic fat accumulation particularly in fatty liver as manifested in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Can-Fite has already received patents for Namodenoson in the treatment of NAFLD/NASH in the U.S. and Korea, and has licensing and distribution agreements for Namodenoson in China and Korea.
InvestmentExpand
Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study
Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly
Can-Fite Announces $8.0 Million Registered Direct Offering
Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S.
Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer
Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office
Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis
Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms
growth-positive
Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET
Can-Fite BioPharma Ltd, a biotechnology company, announced it will conduct a conference call with investors to review the results of its Phase II exploratory NAFLD/NASH study with Namodenoson. The study achieved its primary and secondary efficacy endpoints, while showing continued safety. The results were announced on April 7, 2020. The call will be led by Can-Fite CEO, Dr. Pnina Fishman and the study’s Principal Investigator Dr. Rifaat Safadi. The next steps in the clinical development of Namodenoson for the treatment of NASH will be discussed.
Investment
growth-positive
Can-Fite Gets Approval For COVID-19 Clinical Trial For Piclidenoson In Israel
Israeli biotechnology company Can-Fite BioPharma Ltd. has received approval from the Institutional Review Board at Rabin Medical Center to initiate a pilot clinical study of its drug candidate Piclidenoson for the treatment of moderate-to-severe symptoms in coronavirus infected patients. The company believes that Piclidenosons anti-viral, anti-inflammatory, and anti-rheumatic properties combined with its excellent safety profile make it a strong candidate for the potential treatment of coronavirus. The pilot trial will involve 40 hospitalized COVID-19 infected patients with moderate-to-severe symptomatic disease.
Customers
Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020
https://seekingalpha.com/pr/17812127-can-fite-to-participate-in-digital-bio-europe-spring-partnering-conference-looks-to-partner
Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson
Can-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD
Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and Piclidenoson
Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications
Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea;Results of its NASH Phase II Study are Expected this Quarter
Can-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis
Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects
Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial
https://www.marketwatch.com/press-release/can-fite-granted-patents-for-its-sexual-dysfunction-drug-2019-11-19
Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market
Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients
U.S. FDA Agreed with Can-Fite's Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer
Growth-Positive
Can-Fite BioPharma Interview to Air on Bloomberg International on the RedChip Money Report
Can-Fite BioPharma Ltd., a biotechnology company, announced an interview with CEO Pnina Fishman Ph.D. will air on The RedChip Money Report television program. The interview will discuss the companys robust development pipeline, licensing and milestone payments. Can-Fite BioPharma is an advanced clinical stage drug development company with a platform technology designed to address markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The companys lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis.
Management Changes
Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™
growth-positive
Capital Point's hostile bid for Can-Fite ends in compromise
Can-Fite BioPharma reached a compromise agreement with Capital Point, ending a hostile takeover attempt. Can-Fites CEO, Dr. Pnina Fishman, will continue leading the company, and Capital Point will be employed as a consultant. Can-Fite will pay Capital Point 5% of all future amounts raised, up to $1.3 million. Can-Fites share price rose 7% following the announcement. Can-Fite is a veteran pharma company that develops drugs discovered by Dr. Fishman. The companys share price dropped by 90% last year after a financing round. Can-Fite sued Capital Point and also signed an agreement with Univo Pharmaceuticals for joint development. Capital Point is an investment company mainly held by Shir Roichman and Prof. Yehuda Kahane.
PartnersInvestment
Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine
Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays
Can-Fite to Treat Advanced Liver Cancer Patients with Namodenoson Under Compassionate Use Setting in Israel
growth-positive
Can-Fite BioPharma Signs South Korean Distribution Agreement for Psoriasis Treatment Drug
Can-Fite BioPharma Ltd. has signed a distribution agreement with Kyongbo Pharm Co. Ltd. to distribute Can-Fites psoriasis treatment drug Piclidenoson. The agreement is valued at $750,000 with additional payments of up to $3.25 million depending on milestones. It is contingent upon regulatory approval of the drug, which is currently in phase 3 clinical trials. Can-Fite is a pharmaceutical company that develops small molecule drugs for the treatment of psoriasis, liver and inflammatory diseases, and cancer. In April, the company also signed an expansion of its licensing agreement with Chong Kun Dang Pharmaceuticals for a drug for non-alcoholic steatohepatitis (NASH).
Partners
Findings from Can-Fite's Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session
Can-Fite's Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)
growth-positive
Can-Fite BioPharma Announces $6 Million Registered Direct Offering
Can-Fite BioPharma Ltd. has entered into a definitive agreement with certain institutional investors to receive gross proceeds of $6 million. The company will issue 1,500,000 registered American Depository Shares (ADSs) at a purchase price of $4.00 per ADS in a registered direct offering. Additionally, investors will receive unregistered warrants to purchase one ADS for each ADS purchased. The closing of the offering is expected to take place on or about May 22, 2019.
Investment
growth-positive
Can-Fite BioPharma Receives $1 Million From CKD Pharmaceuticals as Part of Expanded Agreement
Can-Fite BioPharma Ltd. has received a $1 million payment from Chong Kun Dang Pharmaceuticals following the expansion of their licensing agreement. Can-Fite develops drugs for liver and inflammatory diseases and cancer, with the agreement focusing on their drug for non-alcoholic steatohepatitis (NASH). Can-Fite is entitled to up to $5 million more depending on milestones. The company also has a licensing, development, and distribution agreement with CMS Medical Venture Investment Ltd.
Partners
growth-positive
Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting BioSpace
Can-Fite BioPharma announced that the results from its Phase II trial in patients with advanced liver cancer have been accepted for oral presentation at the 54th Annual Meeting of the American Society of Clinical Oncology. The presentation will focus on the efficacy and safety of Namodenoson, Can-Fites drug candidate for hepatocellular carcinoma. The company considers this acceptance as a testament to the compelling data from the Phase II trial and believes it reflects the oncology communitys assessment of the studys high impact and relevance in the treatment of liver cancer. Can-Fite is currently planning a Phase III study for Namodenoson with the support of leading oncologists and regulatory experts.
Investment
growth-positive
Can-Fite BioPharma to Raise $3.2 Million in Direct Offering
Can-Fite BioPharma Ltd. has signed a definitive agreement with undisclosed institutional investors for a $3.2 million direct offering. The company develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer. In 2018, Can-Fite signed a licensing, development, and distribution agreement with CMS Medical Venture Investment Ltd.
Investment
Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson
growth-negative
Can-Fite fights hostile takeover
Can-Fite BioPharma has filed a NIS 40 million lawsuit against Capital Point, a holding company, to halt its hostile takeover attempt. Can-Fites stock has plummeted 85% this year, making it the worst-performing share on the Tel Aviv Stock Exchange. The company raised $6 million a month ago, contributing to the decline and creating an incentive for the takeover. Can-Fite accuses Capital Point of making false reports to the stock exchange and breaching reporting duties to the US Securities and Exchange Commission. Can-Fite is a biotech company developing drugs for inflammatory diseases and cancer.
Partners
growth-positive
Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert
Can-Fite BioPharma Ltd, a biotech company that develops proprietary small molecule drugs for cancer, liver and inflammatory diseases, has commissioned Professor Josep Llovet to assist in the analysis of Phase II data. Llovet is a renowned leader in liver cancer research and development. The data is expected to be released during the first quarter of 2019. Can-Fites drug candidate, Namodenoson, is currently in Phase II clinical trials for the treatment of advanced hepatocellular carcinoma.
Management ChangesExpand
https://ir.canfite.com/press-releases/detail/824/drugs-with-mechanism-of-action-utilized-by-namodenoson-are-recommended-by-leading-u-s-researchers-to-be-developed-to-combat-liver-cancer
growth-positive
Can-Fite BioPharma Announces $5 Million Registered Direct Offering
Can-Fite BioPharma has entered into definitive agreements with institutional investors to receive $5 million in gross proceeds. The company will issue 2,500,000 registered American Depository Shares (ADSs) at a purchase price of $2.00 per ADS in a registered direct offering. The closing of the offering is expected to take place on or about January 24, 2017. Rodman & Renshaw, a unit of H.C. Wainwright & Co., is acting as the exclusive placement agent in connection with this offering.
Investment
growth-positive
Can-Fite Receives $500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea
Can-Fite BioPharma Ltd. has received its first payment of $500,000 from Chong Kun Dang Pharmaceuticals (CKD) as part of a distribution agreement for the exclusive right to distribute Namodenoson (CF102) for the treatment of liver cancer in South Korea. The agreement could see Can-Fite receive up to $3,000,000 in upfront and milestone payments, plus royalties on net sales of 23%. Can-Fite is currently conducting a global Phase II study evaluating the efficacy of Namodenoson as a second-line treatment for advanced hepatocellular carcinoma.
PartnersInvestment
growth-positive
Can-Fite rebounds on revised psoriasis trial analysis
Can-Fite BioPharma Ltd. announced that further analysis of the Phase II/III research data yielded positive data supporting continued development of the drug for psoriasis treatment. The companys share rose 26.3% on the Tel Aviv Stock Exchange.
Customers
growth-positive
Can-Fite jumps on positive rheumatoid arthritis treatment results
Can-Fite BioPharma Ltd. reported positive results in a Phase IIb trial for a rheumatoid arthritis treatment. The study met all its primary efficacy endpoints and showed statistically significant superiority over placebo in reducing signs and symptoms of RA. Can-Fite is a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases.
Customers
Can-Fite BioPharma Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 17 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Can-Fite BioPharma Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 99/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 512022153 |
| Crunchbase | canfite-biopharma |
| Phone | +97239241114 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-04-15T00:00:00.000Z |
| Created | 2014-07-28T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on TASE on Sep, 2005; |